Abstract: Novel processes for making the N-pyrrazole substituted 2-adenosine derivative regadenoson and a novel polymorph thereof. The novel polymorph of regadenoson designated form H and drug substances and pharmaceutical compositions including the novel polymorph H are disclosed.

Abstract: Novel processes for making the N-pyrrazole substituted 2-adenosine derivative regadenoson and a novel polymorph thereof. The novel polymorph of regadenoson designated form H and drug substances and pharmaceutical compositions including the novel polymorph H are disclosed.

Abstract: Novel processes for making the N-pyrrazole substituted 2-adenosine derivative regadenoson and a novel polymorph thereof. The novel polymorph of regadenoson designated form H and drug substances and pharmaceutical compositions including the novel polymorph H are disclosed.

Abstract: Methods are disclosed for making 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide, intermediates and pharmaceutically acceptable salts thereof.

Abstract: Methods are disclosed for making 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide, intermediates and pharmaceutically acceptable salts thereof.

Abstract: A system and method are provided for updating a network including at least one optical circuit switch (OCS) to transition from an existing network topology to a new network topology. One or more intermediate topologies between the existing topology and the new topology are created. Creating the intermediate topologies includes selecting first links to be added to the existing topology without removing links, selecting additional links to be added to the existing topology upon removal of one or more existing links, and adding one or more of the selected first and additional links to the existing topology to create a first intermediate topology. It is determined whether any of the selected first and additional links are still to be added, and if no selected first and additional links are to be added, remaining links are removed. The transition from the existing topology to the first intermediate topology is then effected.

Abstract: Novel polymorphic forms of tavaborole, Form A and Form B, and methods of making same are disclosed. Methods are disclosed for the manufacture of the novel polymorphic Forms A and B. Methods include dissolving tavaborole in a pharmaceutically acceptable solvent to obtain a mixture, heating the mixture until a clear solution is obtained, cooling the clear solution, stirring the clear solution to obtain a crystalline product, filtering the crystalline product, and drying the crystalline product to obtain the pharmaceutically acceptable crystalline form of tavaborole. Pharmaceutical composition are disclosed including a pharmaceutically acceptable crystalline form of tavaborole Form A and/or Form B.

Abstract: Novel processes are disclosed for the preparation of eribulin mesylate. Novel intermediate compounds used in the processes for making eribulin mesylate as well as processes for making the intermediates are disclosed.

Abstract: System and methods for efficiently distributing data packets in a multi-path network while maintaining flow affinity are provided. In one aspect, a system and method includes calculating hash values for distributing different flows, or sets of flows, of data packets received at a routing device. The hash value is calculated not only using information in the data packets, but also based on additional information that is determined based on an N-bit derived from the data packets. In some cases, calculating a hash value based on the additional information increases the entropy of the hashing function, thus enabling a routing device to distribute different flows of data packets over a greater number of network paths. Each routing device can derive a different, and randomly generated N-bit key while maintaining flow affinity for each received data packet in a given flow of data packets.

Abstract: Methods are disclosed for the preparation of netupitant and pharmaceutically acceptable salts thereof which are novel, easily reproducible, environmentally safe and cost effective. The methods may employ inexpensive starting materials and the preparation processes for intermediates are simple and highly reproducible. Novel intermediates for the preparation of netupitant and pharmaceutically acceptable salts thereof are also disclosed. Amorphous netupitant and methods of making same are disclosed.

Abstract: Methods are disclosed for the preparation of netupitant and pharmaceutically acceptable salts thereof which are novel, easily reproducible, environmentally safe and cost effective. The methods may employ inexpensive starting materials and the preparation processes for intermediates are simple and highly reproducible. Novel intermediates for the preparation of netupitant and pharmaceutically acceptable salts thereof are also disclosed. Amorphous netupitant and methods of making same are disclosed.

Abstract: Methods are disclosed for making 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide, intermediates and pharmaceutically acceptable salts thereof.

Abstract: Novel processes for making the N-pyrrazole substituted 2-adenosine derivative regadenoson and a novel polymorph thereof. The novel polymorph of regadenoson designated form H and drug substances and pharmaceutical compositions including the novel polymorph H are disclosed.

Abstract: Network performance may be improved by adjusting a logical network topology while avoiding attendant disruptions. By identifying an alternative logical topology, routing network traffic away from links that will be eliminated from the alternative logical topology, and updating a traffic routing plan upon the adoption of the alternative logical topology, a network may adopt a more efficient topology without misdirecting network traffic.

Abstract: Methods are disclosed for the preparation of netupitant and pharmaceutically acceptable salts thereof which are novel, easily reproducible, environmentally safe and cost effective. The methods may employ inexpensive starting materials and the preparation processes for intermediates are simple and highly reproducible. Novel intermediates for the preparation of netupitant and pharmaceutically acceptable salts thereof are also disclosed. Amorphous netupitant and methods of making same are disclosed.

Abstract: Methods of making saxagliptin, pharmaceutically acceptable salts and hydrates thereof and intermediates thereof.

Abstract: A method and apparatus are provided for communicating congestions that area detected in a communications network. According to the method and apparatus, a first Ethernet frame encapsulating a first PDU is transmitted across an Ethernet network. Congestion in the network is then detected, and an indication of the congestion is inserted in a predetermined header field of the first Ethernet frame. Once the first Ethernet frame is received by an endpoint in the network, the indication of congestion is transferred into a second PDU that is associated with the first PDU. The second PDU is then encapsulated in a second Ethernet frame and transmitted towards the sender of the first PDU.

Abstract: Processes are disclosed for the synthesis of the Factor Xa anticoagulant fondaparinux and related compounds. Protected pentasaccharide intermediates and efficient and scalable processes for the industrial scale production of fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions are provided.

Abstract: Methods of making saxagliptin, pharmaceutically acceptable salts and hydrates thereof and intermediates thereof.

Abstract: System and methods for efficiently distributing data packets in a multi-path network having a plurality of equal cost paths each having the same number of hops are provided. In one aspect, a system and method includes reordering the entries in the routing table of one or more peer routing devices, such that succeeding equal cost next hop routing devices that are interconnected in a Clos formation to the peer routing devices received unbiased traffic from each of the peer routing devices, thus enabling the succeeding next hop routing devices to distribute data traffic evenly over additional equal cost multiple hops further into the network.